Ixazomib-Based Frontline Therapy in Patients with Newly Diagnosed Multiple Myeloma in Real-Life Practice Showed Comparable Efficacy and Safety Profile with Those Reported in Randomized Clinical Trials: A Multi-Center Study in China
机构：[1]Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China[2]Department of Hematology, Beijing Jishuitan Hospital, Beijing, China[3]Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China[4]The First Affiliated Hospital of Xiamen University, Xiamen, China[5]Wuxi People Hospital, WuXi, China[6]Anhui Provincial Cancer Hospital, Hefei, China[7]Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China[8]Shengjing Hospital of China Medical University, Shengjing, China中国医科大学附属盛京医院中国医科大学盛京医院[9]The Second Affiliated Hospital of Soochow University, Suzhou, China苏州大学附属第二医院[10]Department of Hematology, The First Affiliated Hospital ofSoochow University, Jiangsu Institute of Hematology, Suzhou, China[11]Department of Hematology, Nanjing University Medical School,the Affiliated Nanjing Drum Tower Hospital, Nanjing, China[12]The Affiliated Hospital of Hebei University, Baoding, China河北大学附属医院[13]Zhujiang Hospital of Southern Medical University, Guangzhou, China南方医科大学珠江医院[14]The First Affiliated Hospital of Guangxi Medical University, Guangxi, China
第一作者机构：[1]Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China
共同第一作者：
推荐引用方式(GB/T 7714)：
Li Jing,Bao Li,Xia Zhong-jun,et al.Ixazomib-Based Frontline Therapy in Patients with Newly Diagnosed Multiple Myeloma in Real-Life Practice Showed Comparable Efficacy and Safety Profile with Those Reported in Randomized Clinical Trials: A Multi-Center Study in China[J].BLOOD.2019,134:doi:10.1182/blood-2019-128614.
APA：
Li, Jing,Bao, Li,Xia, Zhong-jun,Wang, Sili,Zhou, Xin...&Liu, Peng.(2019).Ixazomib-Based Frontline Therapy in Patients with Newly Diagnosed Multiple Myeloma in Real-Life Practice Showed Comparable Efficacy and Safety Profile with Those Reported in Randomized Clinical Trials: A Multi-Center Study in China.BLOOD,134,
MLA：
Li, Jing,et al."Ixazomib-Based Frontline Therapy in Patients with Newly Diagnosed Multiple Myeloma in Real-Life Practice Showed Comparable Efficacy and Safety Profile with Those Reported in Randomized Clinical Trials: A Multi-Center Study in China".BLOOD 134.(2019)
医学